Real-life outcomes of benralizumab treatment in chronic rhinosinusitis with nasal polyps: The BenREALizumab Study.

Juan Maza-Solano, Vicente Merino-Bohórquez, Ana Gómez-Bastero, Julio Delgado-Romero, Serafín Sánchez-Gomez
{"title":"Real-life outcomes of benralizumab treatment in chronic rhinosinusitis with nasal polyps: The BenREALizumab Study.","authors":"Juan Maza-Solano, Vicente Merino-Bohórquez, Ana Gómez-Bastero, Julio Delgado-Romero, Serafín Sánchez-Gomez","doi":"10.1016/j.otoeng.2025.512291","DOIUrl":null,"url":null,"abstract":"<p><p>Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease with a significant impact on quality of life. Benralizumab has shown efficacy in severe eosinophilic asthma, but there is limited evidence for CRSwNP. A prospective observational study was conducted in a tertiary hospital with six adults with severe CRSwNP, according to EPOS2020 criteria, treated for 52 weeks. All had multiple surgeries (mean 3.3) and high cumulative exposure to systemic corticosteroids. Initially, they presented a high symptom and endoscopic burden (SNOT-22: 72; NPS: 5.2). After 16 and 52 weeks, significant improvements were observed in SNOT-22 (40.3 and 28.8), NPS (4.3 and 2.7), corticosteroid use, and complete eosinophil depletion. VAS scores improved, especially in smell, rhinorrhea, and general condition. No significant adverse events occurred. These preliminary results suggest that benralizumab may be effective in CRSwNP without associated asthma, although larger controlled studies are needed.</p>","PeriodicalId":93855,"journal":{"name":"Acta otorrinolaringologica espanola","volume":" ","pages":"512291"},"PeriodicalIF":0.0000,"publicationDate":"2025-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta otorrinolaringologica espanola","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.otoeng.2025.512291","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease with a significant impact on quality of life. Benralizumab has shown efficacy in severe eosinophilic asthma, but there is limited evidence for CRSwNP. A prospective observational study was conducted in a tertiary hospital with six adults with severe CRSwNP, according to EPOS2020 criteria, treated for 52 weeks. All had multiple surgeries (mean 3.3) and high cumulative exposure to systemic corticosteroids. Initially, they presented a high symptom and endoscopic burden (SNOT-22: 72; NPS: 5.2). After 16 and 52 weeks, significant improvements were observed in SNOT-22 (40.3 and 28.8), NPS (4.3 and 2.7), corticosteroid use, and complete eosinophil depletion. VAS scores improved, especially in smell, rhinorrhea, and general condition. No significant adverse events occurred. These preliminary results suggest that benralizumab may be effective in CRSwNP without associated asthma, although larger controlled studies are needed.

慢性鼻窦炎伴鼻息肉(CRSwNP)是一种显著影响生活质量的2型炎症性疾病。Benralizumab已显示出对严重嗜酸性粒细胞性哮喘的疗效,但对CRSwNP的证据有限。在一家三级医院进行了一项前瞻性观察研究,根据EPOS2020标准,6名患有严重CRSwNP的成年人接受了52周的治疗。所有患者都接受过多次手术(平均3.3次),并且全身皮质类固醇的累积暴露量很高。最初,他们表现出很高的症状和内镜负担(SNOT-22: 72; NPS: 5.2)。16周和52周后,观察到SNOT-22(40.3和28.8)、NPS(4.3和2.7)、皮质类固醇使用和完全嗜酸性粒细胞消耗的显著改善。VAS评分有所改善,尤其是在嗅觉、鼻漏和一般情况方面。无明显不良事件发生。这些初步结果表明,尽管需要更大规模的对照研究,但benralizumab可能对没有相关哮喘的CRSwNP有效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信